Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Receives Consensus Recommendation of “Hold” from Analysts

Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) have been given an average rating of “Hold” by the five analysts that are currently covering the stock, Marketbeat reports. One analyst has rated the stock with a sell rating, two have given a hold rating and two have given a buy rating to the company. The average 12-month price objective among brokerages that have issued a report on the stock in the last year is $8.10.

RXRX has been the subject of a number of recent research reports. Needham & Company LLC reaffirmed a “buy” rating and issued a $8.00 target price on shares of Recursion Pharmaceuticals in a research note on Thursday, May 7th. Weiss Ratings reissued a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a report on Friday, July 17th. Morgan Stanley raised their price objective on shares of Recursion Pharmaceuticals from $5.00 to $5.50 and gave the stock an “equal weight” rating in a research report on Thursday, May 14th. Finally, JPMorgan Chase & Co. reduced their target price on shares of Recursion Pharmaceuticals from $11.00 to $10.00 and set an “overweight” rating on the stock in a research note on Thursday, April 30th.

Recursion Pharmaceuticals Price Performance

Shares of Recursion Pharmaceuticals stock traded up $0.01 on Thursday, hitting $2.98. 1,267,447 shares of the company were exchanged, compared to its average volume of 18,477,324. The company has a quick ratio of 5.47, a current ratio of 5.47 and a debt-to-equity ratio of 0.01. The company has a 50-day moving average price of $3.32 and a 200 day moving average price of $3.52. The stock has a market capitalization of $1.58 billion, a price-to-earnings ratio of -2.48 and a beta of 1.00. Recursion Pharmaceuticals has a 1-year low of $2.77 and a 1-year high of $7.18.

Recursion Pharmaceuticals (NASDAQ:RXRX) last posted its quarterly earnings results on Wednesday, May 6th. The company reported ($0.22) EPS for the quarter, beating the consensus estimate of ($0.30) by $0.08. The firm had revenue of $6.47 million during the quarter, compared to analysts’ expectations of $15.78 million. Recursion Pharmaceuticals had a negative return on equity of 54.33% and a negative net margin of 842.95%.The business’s revenue for the quarter was down 56.8% on a year-over-year basis. During the same quarter last year, the firm earned ($0.50) earnings per share. As a group, sell-side analysts predict that Recursion Pharmaceuticals will post -0.99 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, Director Blake Borgeson sold 40,000 shares of the company’s stock in a transaction on Tuesday, July 7th. The stock was sold at an average price of $3.96, for a total value of $158,400.00. Following the transaction, the director owned 6,218,287 shares of the company’s stock, valued at $24,624,416.52. This represents a 0.64% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Najat Khan sold 23,588 shares of the stock in a transaction on Friday, June 5th. The stock was sold at an average price of $3.58, for a total value of $84,445.04. Following the transaction, the chief executive officer owned 2,175,796 shares of the company’s stock, valued at approximately $7,789,349.68. This represents a 1.07% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 131,937 shares of company stock valued at $486,974 in the last 90 days. Insiders own 6.65% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the stock. Vanguard Group Inc. increased its position in shares of Recursion Pharmaceuticals by 18.6% during the fourth quarter. Vanguard Group Inc. now owns 47,187,759 shares of the company’s stock valued at $192,998,000 after acquiring an additional 7,407,606 shares during the last quarter. State Street Corp boosted its position in shares of Recursion Pharmaceuticals by 38.7% during the 4th quarter. State Street Corp now owns 25,333,888 shares of the company’s stock worth $103,616,000 after purchasing an additional 7,064,963 shares during the period. Norges Bank acquired a new stake in Recursion Pharmaceuticals in the 4th quarter valued at approximately $23,473,000. ARK Investment Management LLC raised its position in Recursion Pharmaceuticals by 11.2% in the fourth quarter. ARK Investment Management LLC now owns 37,316,856 shares of the company’s stock valued at $152,626,000 after purchasing an additional 3,771,357 shares during the period. Finally, Renaissance Technologies LLC acquired a new position in Recursion Pharmaceuticals during the first quarter worth $7,370,000. Institutional investors and hedge funds own 89.06% of the company’s stock.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc (NASDAQ: RXRX) is a biopharmaceutical company that combines advanced automation, artificial intelligence and high-throughput biology to discover and develop novel therapeutics. The company’s proprietary platform integrates deep-learning algorithms with large-scale cellular imaging and chemical biology, enabling the rapid identification of potential drug candidates across a range of indications. By automating complex laboratory workflows and leveraging computational models, Recursion aims to accelerate the drug discovery process and expand the scope of targets that can be addressed.

At the core of Recursion’s offering is its digital biology platform, which captures billions of cell images under varying chemical and genetic perturbations.